Safety and effectiveness of lu-177 dotatate prrt after regional hepatic radio or chemo embolization in patients with somatostatin expressing neuroendocrine tumors

M Hamiditabar, G Vahdati, R Amerinia, E Delpassand - 2016 - Soc Nuclear Med
1436 Objectives There are several therapeutic modalities for management of somatostatin
receptor expressing neuroendocrine neoplasms. Peptide Receptor Radionuclide Therapy …
Save Cite Cited by 1 Related articles
[PDF] academia.edu

Safety and effectiveness of 177Lu-DOTATATE peptide receptor radionuclide therapy after regional hepatic embolization in patients with somatostatin-expressing …

M Hamiditabar, M Ali, L Bolek, G Vahdati… - Clinical nuclear …, 2017 - journals.lww.com
Purpose Peptide receptor radionuclide therapy (PRRT) with 177 Lu-DOTATATE is shown to
be an effective therapeutic option for somatostatin-expressing neuroendocrine neoplasms …
Save Cite Cited by 17 Related articles All 5 versions

Assessment of hepatotoxicity with 177Lu-DOTATATE

J Trak, B Cagnut, S Gavane, N Ghesani, M Ghesani… - 2023 - Soc Nuclear Med
P1170 Introduction: Peptide receptor radionuclide therapy (PRRT) with radiolabeled
somatostatin receptor (SSR) analogs is now an established systemic treatment for …
Save Cite Related articles

Toxicity of sequential treatment with radioembolization and PRRT in hepatic metastasized neuroendocrine tumors

J Geisler, C Auernhammer, C Zech, P Bartenstein… - 2012 - Soc Nuclear Med
1189 Objectives In metastatic neuroendocrine tumors (NET) peptide receptor radionuclide
therapy (PRRT) using radiolabelled somatostatin analogues (Y-90-/Lu-177-DOTATATE) and …
Save Cite Cited by 8 Related articles
[HTML] oup.com

Evaluation of liver and renal toxicity in peptide receptor radionuclide therapy for somatostatin receptor expressing tumors: a 2-year follow-up

H Duan, V Ferri, GA Fisher, S Shaheen… - The …, 2022 - academic.oup.com
Background Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin
receptor (SSR) analogs is now an established systemic treatment for neuroendocrine tumors …
Save Cite Cited by 5 Related articles All 6 versions

Intra-arterial PRRT of SSTR-expressing tumors in patients with hepatic only versus extrahepatic tumor: efficacy and safety evaluation

A Singh, J Zhang, H Kulkarni, R Baum - 2019 - Soc Nuclear Med
625 Objectives: Intravenous peptide receptor radionuclide therapy (PRRT) has established
its role in the treatment algorithm of somatostatin receptor (SSTR) expressing …
Save Cite Cited by 7 Related articles
[PDF] snmjournals.orgFree from Publisher

90Y radioembolization in the treatment of neuroendocrine neoplasms: results of an international multicenter retrospective study

BM Schaarschmidt, M Wildgruber… - Journal of Nuclear …, 2022 - Soc Nuclear Med
In neuroendocrine neoplasms (NENs), the presence of distant metastases has a severe
impact on survival leading to a relevant decrease in the 5-y survival rate. Here, 90Y …
Save Cite Cited by 16 Related articles All 5 versions
[PDF] researchgate.net

Successful intra-arterial peptide receptor radionuclide therapy of DOTATOC-negative high-grade liver metastases of a pancreatic neuroendocrine neoplasm using …

J Zhang, HR Kulkarni, A Singh… - Clinical Nuclear …, 2020 - journals.lww.com
Radiolabeled somatostatin receptor (SSTR) antagonists have shown promise for imaging
neuroendocrine neoplasms and the superiority to SSTR agonists, with lower liver …
Save Cite Cited by 5 Related articles All 5 versions
[HTML] springer.com

[HTML][HTML] Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA0-Tyr3-octreotate in combination with amino acid solution infusion in …

N Kobayashi, S Takano, K Ito, M Sugiura… - Annals of Nuclear …, 2021 - Springer
Purpose Peptide receptor radionuclide therapy (PRRT) with 177 Lu-DOTA 0-Tyr 3-octreotate
(177 Lu-DOTATATE) is one of the most reliable treatments for unresectable, progressive …
Save Cite Cited by 11 Related articles All 9 versions
[PDF] viamedica.pl

Hepatic complications of peptide receptor radionuclide therapy with Lutetium-177 and Yttrium-90 in patients with neuroendocrine neoplasm

B Bober, M Saracyn, A Lubas… - Nuclear Medicine …, 2022 - journals.viamedica.pl
Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors originating from
neuroendocrine cells spread throughout the body, forming the so-called diffuse endocrine …
Save Cite Cited by 2 Related articles All 6 versions View as HTML